By Dr. Quoc Dang

Medical Director, WeightLossPills.com

The conversation around weight loss medication has changed dramatically in the past few years. GLP-1 receptor agonists like semaglutide and tirzepatide have produced results that were previously out of reach for most people struggling with obesity, and the clinical data supporting them is substantial. But the enthusiasm for these medications has also led to a wave of people pursuing them who may not fully understand what candidacy actually means, or what the treatment involves beyond the first injection.

I want to be direct about this: weight loss medications are not right for everyone, and more importantly, they are not necessary for everyone who wants to lose weight. The question of whether you are a good candidate is worth thinking through carefully before you pursue a prescription, because starting the wrong treatment at the wrong time rarely produces the best outcomes.

What Candidacy Actually Means Clinically

The FDA-approved indications for GLP-1 weight loss medications like Wegovy (semaglutide) and Zepbound (tirzepatide) are fairly specific. Both are indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher if the person has at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea. These criteria were established based on the populations studied in the clinical trials, where the benefits were clearest.

This means someone with a BMI of 25 who wants to lose ten pounds is not, clinically speaking, a candidate for these medications under current guidelines. That is not a judgment on their desire to lose weight. It reflects the fact that the benefit-risk profile for medications with real side effects and significant costs looks very different when the weight-related health risk is lower.

If you fall within the BMI range and have relevant comorbidities, you meet the basic eligibility threshold. But meeting that threshold is the starting point, not the conclusion. There are several other factors worth evaluating before deciding whether medication is the right approach for your situation.

Contraindications You Should Know Before You Ask

Some patients are not candidates for GLP-1 medications regardless of their BMI or health goals. The clearest contraindications are a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Both semaglutide and tirzepatide carry a black box warning about a potential association with thyroid C-cell tumors based on animal studies. While the translation to human risk remains under investigation, anyone with this history should not take these medications.

Pancreatitis history is another consideration. GLP-1 medications have been associated with cases of acute pancreatitis, and patients with a prior pancreatitis episode should discuss this carefully with their prescriber before starting. Severe gastroparesis, a condition where stomach emptying is already significantly delayed, is generally considered a contraindication because GLP-1 medications further slow gastric emptying as part of their mechanism.

Pregnancy is an absolute contraindication. These medications should be stopped at least two months before a planned pregnancy. Women of childbearing age should discuss contraception planning with their prescriber as part of the initial conversation.

The Question Behind the Question: Have You Done the Baseline Work?

This is the part of the candidacy conversation that rarely appears in the eligibility criteria but matters enormously in practice. Weight loss medications work most effectively when they are part of a broader approach that includes dietary changes, physical activity, and behavioral modification. They reduce hunger significantly, which creates an opportunity to build different habits. But they do not automatically install those habits.

Patients who get the best outcomes from GLP-1 medications tend to be those who have already tried structured lifestyle approaches and have some experience with what works and does not work for them personally. They understand, going in, that the medication is a tool for reducing a biological barrier to change, not a replacement for the change itself. Patients who start medication as a first resort, before making any dietary or activity modifications, often find that the results are less durable because the foundational habits are not there when the hunger suppression fades.

None of this means you need to have already lost significant weight before starting. It means having a realistic sense of what the medication does and does not do, and having some plan for what you will do differently during the period when the medication is working.

Mental Health Considerations That Are Often Overlooked

GLP-1 medications can affect mood and, in some patients, have been associated with changes in emotional eating patterns, depression, or anxiety. The FDA has added language to labeling about suicidal ideation, though the causal evidence remains debated in the literature. What is clearer is that significant weight loss of any kind can surface psychological material that was not apparent before: changes in how people relate to food, shifts in identity and self-perception, and sometimes difficult emotional responses to rapid physical change.

Patients with a history of eating disorders require particularly careful evaluation before starting. The appetite suppression these medications produce can interact in complex ways with restrictive eating patterns, and the framing of the medication as a tool for eating less can be problematic for some individuals. This is not an automatic disqualification, but it requires an informed conversation with both a prescribing physician and, ideally, a mental health professional familiar with eating disorders.

I raise this not to discourage anyone from considering medication, but because the prescribing conversation does not always go deep enough into these areas. Knowing what to watch for and having support in place before you start puts you in a better position than discovering these dynamics after the fact.

Can You Sustain the Treatment Long Term?

This question sounds like a logistical one, but it is actually a clinical one. The data from the STEP 1 extension trial showed that patients who stopped semaglutide regained approximately two-thirds of their lost weight within a year. GLP-1 medications treat obesity the way blood pressure medications treat hypertension: the condition is managed while the medication is taken, and it returns when it is stopped. For most patients, this means the treatment framework is long-term.

Understanding the realistic cost and coverage landscape before you start matters because access interruptions are one of the most common reasons for early discontinuation. Both Wegovy and Zepbound have list prices exceeding one thousand dollars per month without coverage. Insurance coverage has been expanding but remains inconsistent. Manufacturer savings programs can substantially reduce out-of-pocket costs for commercially insured patients who qualify. Staying current on which options are available, including newer alternatives like oral orforglipron, is worth doing before your first prescription is written. Resources that track this landscape can be helpful during the planning phase, including WeightLossPills.com, which maintains updated information on coverage options and costs across available medications.

A patient who can access the medication consistently for one to two years is in a fundamentally different position from one who starts, loses coverage after four months, and then regains what they lost. Thinking through the sustainability question upfront is not pessimism. It is how you avoid building a treatment plan on a foundation that will not hold.

Signs That Medication Is Probably the Right Next Step

After reviewing all of this, what does a good candidate actually look like? In my clinical experience, the patients who do best on GLP-1 medications tend to share a few characteristics. They meet the BMI criteria and have at least one weight-related health condition that has not responded adequately to lifestyle changes alone. They have tried structured approaches to eating and activity and have a realistic sense of what has and has not worked. They are not approaching the medication as a short-term fix, and they understand that the results require ongoing management.

They also have access to a prescriber who will actively manage their treatment rather than simply writing the prescription and checking in annually. Dose titration, side effect management, and periodic reassessment of goals all require ongoing contact. Patients who are treated well by an engaged prescriber have substantially better outcomes than those who are left to navigate the medication on their own.

If you are looking at this list and feeling uncertain about one or two of these factors, that does not mean you should not pursue the conversation with your doctor. It means you should have that specific uncertainty on the table when you do. The prescribing conversation is most productive when you already know what you are bringing to it.

Signs That Medication May Not Be the Right Fit Right Now

Not every patient who qualifies on paper is well-positioned to start. A few situations where I would encourage someone to think carefully before pursuing a prescription: they have contraindications they have not fully discussed with a knowledgeable prescriber, they are in a period of significant life instability that makes consistent treatment adherence difficult, they have an eating disorder history they have not addressed with a mental health professional, or they have not yet engaged seriously with the lifestyle changes that will determine how durable their results are.

None of these are permanent disqualifications. They are reasons to do some groundwork before starting, so that when you do, you are in the best position to get the most from it. The urgency many patients feel to start immediately is understandable. But the medications will still be available in three months, and three months of preparation often translates into meaningfully better outcomes.

The Bottom Line

Good candidacy for weight loss medication is not just about BMI and comorbidities, though those are the starting point. It is also about contraindications, mental health context, realistic expectations about long-term treatment, and whether you have the access and support structure to sustain it. The patients who get the most from these medications are the ones who walked into their first appointment with some of this thinking already done.

If you are in the process of evaluating whether this is the right step for you, the goal should not be to convince yourself or your doctor in either direction. It should be to have enough information that the decision, whichever way it goes, is one you made with clarity.

Dr. Quoc Dang

Medical Director, WeightLossPills.com